Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

You must log in to access content on this page. Or click here to request access.
Advancing fluorescent tracer agents and their transdermal detection.

The goal of MediBeacon’s fluorescent tracer agent-based systems is to provide clinically relevant information that can cost effectively and positively impact patient care.

Accurate physiological measurements made at the point of care, are vital in the critical care setting as well as in the management of chronic diseases. Fluorescent tracer agent-based monitoring systems are well positioned to provide measured GFR, GI permeability quantification, enhanced visualization of the vasculature during ocular angiography, and identification of the ureters during abdominal surgeries.*

The goals in the development of fluorescent tracer agents for physiological monitoring are to:
  • Engineer molecules that do not interact with the body.
  • Optimize molecules so they may be optimally detected by transdermal sensors.


The MediBeacon Transdermal GFR Measurement System (TGFR) is comprised of three distinct parts.

Lumitrace™ (relmapirazin) a novel and proprietary fluorescent tracer agent is intravenously administered to a patient and then subsequently excreted from the body by the kidneys.

A small transdermal sensor containing the light source and photo detector for the noninvasive detection of the transdermal fluorescence from Lumitrace™ is attached to one of several positions on the body using a biocompatible adhesive. This transdermal sensor has a built-in cable that connects to the monitor.

The display monitor provides power to the transdermal sensor, digitizes the data acquired from the sensor, contains the algorithms to run the sensor and convert the output to GFR, and displays the GFR to the clinician and/or caregiver.

Together, the components described above are designed to allow the determination of measured GFR. The goal of the TGFR is to provide a minimally invasive measure of the change in patient levels of tracer agent over time via the transdermal sensor placed on the patient’s skin. The rate of decrease in the emitted fluorescence from Lumitrace™ (relmapirazin) is automatically calculated and displayed on the monitor thus yielding a continuous measured Glomerular Filtration Rate (mGFR) or kidney function. Watch the animation.

MB-102 brand name is Lumitrace™


Orally administered fluorescent tracer agents
The oral administration of fluorescent tracer agents coupled with transdermal detection technology is being adapted to provide clinically practical measurement of gut permeability.


Patient administered fluorescent tracer agent-based systems focus on the adaptation of fluorescent tracer agent-based systems for use in the outpatient and eventually, in-home setting are important initiatives.